Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Core Viewpoint - Mineralys Therapeutics, Inc. has announced a public offering of $250 million in common stock to fund clinical development and other corporate purposes [1][3]. Group 1: Offering Details - The company is commencing an underwritten public offering of$250 million, with an option for underwriters to purchase an additional $37.5 million [1]. - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1]. - Joint book-running managers for the offering include BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel, and Wells Fargo Securities [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund clinical development of lorundrostat, including research, development, manufacturing, and pre-commercialization activities [3]. - Additional funds will be allocated for working capital and general corporate purposes [3]. Group 3: Company Overview - Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases related to dysregulated aldosterone [6]. - The company's lead product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor [6].